GB0428394D0 - Saccharide conjugate vaccines - Google Patents

Saccharide conjugate vaccines

Info

Publication number
GB0428394D0
GB0428394D0 GBGB0428394.1A GB0428394A GB0428394D0 GB 0428394 D0 GB0428394 D0 GB 0428394D0 GB 0428394 A GB0428394 A GB 0428394A GB 0428394 D0 GB0428394 D0 GB 0428394D0
Authority
GB
United Kingdom
Prior art keywords
compositions
carrier protein
conjugates
conjugate vaccines
pathogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0428394.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Priority to GBGB0428394.1A priority Critical patent/GB0428394D0/en
Publication of GB0428394D0 publication Critical patent/GB0428394D0/en
Priority to CN2005800474204A priority patent/CN101111261B/zh
Priority to NZ593954A priority patent/NZ593954A/xx
Priority to NZ556486A priority patent/NZ556486A/en
Priority to CA2594524A priority patent/CA2594524C/en
Priority to BRPI0519232-3A priority patent/BRPI0519232A2/pt
Priority to ES05850768T priority patent/ES2356670T3/es
Priority to AU2005317683A priority patent/AU2005317683B2/en
Priority to PCT/IB2005/004050 priority patent/WO2006067632A2/en
Priority to AT05850768T priority patent/ATE492290T1/de
Priority to EP05850768A priority patent/EP1838345B1/en
Priority to JP2007547709A priority patent/JP5737824B2/ja
Priority to RU2007127993/10A priority patent/RU2454244C2/ru
Priority to US11/793,996 priority patent/US20080260773A1/en
Priority to DE602005025531T priority patent/DE602005025531D1/de
Priority to JP2012267162A priority patent/JP2013049717A/ja
Priority to US14/451,907 priority patent/US20150165019A1/en
Priority to JP2015105889A priority patent/JP2015155464A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB0428394.1A 2004-12-24 2004-12-24 Saccharide conjugate vaccines Ceased GB0428394D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0428394.1A GB0428394D0 (en) 2004-12-24 2004-12-24 Saccharide conjugate vaccines
DE602005025531T DE602005025531D1 (de) 2004-12-24 2005-12-23 Saccharid-konjugatvakzine
PCT/IB2005/004050 WO2006067632A2 (en) 2004-12-24 2005-12-23 Saccharide conjugate vaccines
EP05850768A EP1838345B1 (en) 2004-12-24 2005-12-23 Saccharide conjugate vaccines
NZ556486A NZ556486A (en) 2004-12-24 2005-12-23 Multivalent conjugates of two or more saccharide antigens conjugated to a carrier protein as a vaccine
CA2594524A CA2594524C (en) 2004-12-24 2005-12-23 Saccharide conjugate vaccines
BRPI0519232-3A BRPI0519232A2 (pt) 2004-12-24 2005-12-23 vacinas de conjugados de sacarÍdeos
ES05850768T ES2356670T3 (es) 2004-12-24 2005-12-23 Vacunas de conjugados de sacáridos.
AU2005317683A AU2005317683B2 (en) 2004-12-24 2005-12-23 Saccharide conjugate vaccines
CN2005800474204A CN101111261B (zh) 2004-12-24 2005-12-23 糖偶联物疫苗
AT05850768T ATE492290T1 (de) 2004-12-24 2005-12-23 Saccharid-konjugatvakzine
NZ593954A NZ593954A (en) 2004-12-24 2005-12-23 Saccharide conjugate vaccines comprising CD4+ T cell epitopes selected from tetanus toxin, Plasmodium falciparum circumsporozoite protein (PfCSP), Hepatitis B virus nucleocapsid (HBVnc), Influenza virus haemagglutinin (HA), Hepatitis B virus surface antigen (HBsAg) and Influenza virus matrix protein (MT) and a saccharide antigen
JP2007547709A JP5737824B2 (ja) 2004-12-24 2005-12-23 糖結合体ワクチン
RU2007127993/10A RU2454244C2 (ru) 2004-12-24 2005-12-23 Сахарид-конъюгатные вакцины
US11/793,996 US20080260773A1 (en) 2004-12-24 2005-12-23 Saccharide Conjugate Vaccines
JP2012267162A JP2013049717A (ja) 2004-12-24 2012-12-06 糖結合体ワクチン
US14/451,907 US20150165019A1 (en) 2004-12-24 2014-08-05 Saccharide Conjugate Vaccines
JP2015105889A JP2015155464A (ja) 2004-12-24 2015-05-25 糖結合体ワクチン

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428394.1A GB0428394D0 (en) 2004-12-24 2004-12-24 Saccharide conjugate vaccines

Publications (1)

Publication Number Publication Date
GB0428394D0 true GB0428394D0 (en) 2005-02-02

Family

ID=34130952

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0428394.1A Ceased GB0428394D0 (en) 2004-12-24 2004-12-24 Saccharide conjugate vaccines

Country Status (14)

Country Link
US (2) US20080260773A1 (enExample)
EP (1) EP1838345B1 (enExample)
JP (3) JP5737824B2 (enExample)
CN (1) CN101111261B (enExample)
AT (1) ATE492290T1 (enExample)
AU (1) AU2005317683B2 (enExample)
BR (1) BRPI0519232A2 (enExample)
CA (1) CA2594524C (enExample)
DE (1) DE602005025531D1 (enExample)
ES (1) ES2356670T3 (enExample)
GB (1) GB0428394D0 (enExample)
NZ (2) NZ593954A (enExample)
RU (1) RU2454244C2 (enExample)
WO (1) WO2006067632A2 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788796B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788797B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788794B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788798B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788795B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
HU227893B1 (en) * 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
WO2002020059A2 (en) * 2000-09-01 2002-03-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
IL154853A0 (en) * 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
BRPI0708849B1 (pt) 2006-03-17 2022-05-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para a preparação de conjugados imunogênicos multivalentes complexos, os referidos conjugados, e composições farmacêuticas
DK2601969T3 (en) 2006-09-29 2016-04-18 Takeda Vaccines Inc Norovirus vaccine formulations
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
SG184733A1 (en) 2007-09-18 2012-10-30 Ligocyte Pharmaceuticals Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR20110009158A (ko) * 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AU2009268937A1 (en) * 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
CA2733589C (en) 2008-08-08 2021-07-13 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
CN105535955B (zh) * 2009-06-16 2019-04-23 中央研究院 Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
BR112012009014B8 (pt) * 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
CA2779506A1 (en) * 2009-10-02 2011-04-07 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
AU2011316924A1 (en) * 2010-10-20 2013-05-02 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
KR101839496B1 (ko) * 2011-06-01 2018-03-19 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
DK3299030T3 (da) 2011-07-11 2022-09-05 Takeda Vaccines Inc Parenterale norovirus-vaccineformuleringer
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
US10722569B2 (en) 2012-07-05 2020-07-28 Children's Medical Center Corporation Bacterial biofilm matrix as a platform for protein delivery
WO2014013375A1 (en) 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof
BR112015007126A2 (pt) * 2012-10-02 2017-08-08 Glaxosmithkline Biologicals Sa composição, método para induzir uma resposta imune, e, uso de uma composição
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
CN104069504B (zh) * 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
CN104004085B (zh) * 2014-05-28 2017-01-11 山东大学 一种结核杆菌lam寡糖缀合物及其制备方法与应用
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
TWI756893B (zh) * 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CR20180350A (es) 2015-12-04 2018-10-02 Dana Farber Cancer Inst Inc Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer
CA3025524C (en) * 2016-06-02 2023-03-07 Zoetis Services Llc Composition comprising turkey rhinotracheitis and infectious bronchitis strain qx antigens, with cpg oligonucleotide in an oil emulsion
WO2017219004A2 (en) * 2016-06-17 2017-12-21 Children's Medical Center Corporation Biofilm matrix-boosted vaccine
US11097000B2 (en) * 2016-10-03 2021-08-24 National Taiwan University Klebsiella pneumoniae capsule polysaccharide vaccines
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US11305001B2 (en) 2017-03-28 2022-04-19 The Children's Medical Center Corporation Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof
KR20240018698A (ko) * 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN111065417B (zh) 2017-06-23 2024-04-19 美商艾芬尼维克斯公司 免疫原性组合物
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
SG11202101973YA (en) 2018-09-12 2021-03-30 Childrens Medical Ct Corp Pneumococcal fusion protein vaccines
PE20211112A1 (es) 2018-09-12 2021-06-22 Affinivax Inc Vacunas neumococicas multivalentes
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
WO2021158440A1 (en) * 2020-02-06 2021-08-12 Longhorn Vaccines And Diagnostics, Llc Immunogenic compositions to treat and prevent microbial infections
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
CN113150084B (zh) * 2021-03-23 2023-03-21 江苏坤力生物制药有限责任公司 一种纳米化的冠状病毒抗原及其应用
CN113274489B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种预防真菌感染的几丁质寡糖疫苗及其制备方法
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
CN114767846B (zh) * 2022-04-21 2025-10-14 中国医学科学院医学生物学研究所 一种轮状非结构蛋白4在提高重组轮状病毒亚单位疫苗免疫功能中的应用
CN115721711B (zh) * 2022-10-28 2024-01-23 普大生物科技(泰州)有限公司 一种肺炎球菌荚膜多糖-带状疱疹病毒重组蛋白结合疫苗及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
HU9201966D0 (en) * 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
ATE400295T1 (de) * 1995-06-07 2008-07-15 Glaxosmithkline Biolog Sa Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein
PL323863A1 (en) * 1995-06-23 1998-04-27 Smithkline Beecham Biolog Vaccine containing a conjugate of polysaccharidic antigen with proteinous carrier and free proteinous carrier
EP0969873B1 (en) * 1997-03-27 2006-06-07 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
DK1355673T3 (da) * 2001-01-23 2012-09-17 Sanofi Pasteur Inc Multivalent meningococvaccine bestående af et polysaccharid/proteinkonjugat
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae

Also Published As

Publication number Publication date
CA2594524C (en) 2015-05-19
JP5737824B2 (ja) 2015-06-17
DE602005025531D1 (de) 2011-02-03
CN101111261B (zh) 2013-03-27
BRPI0519232A2 (pt) 2009-01-06
EP1838345B1 (en) 2010-12-22
NZ556486A (en) 2011-07-29
NZ593954A (en) 2013-07-26
JP2015155464A (ja) 2015-08-27
JP2013049717A (ja) 2013-03-14
AU2005317683A1 (en) 2006-06-29
WO2006067632A3 (en) 2007-03-29
CN101111261A (zh) 2008-01-23
CA2594524A1 (en) 2006-06-29
EP1838345A2 (en) 2007-10-03
WO2006067632A2 (en) 2006-06-29
ATE492290T1 (de) 2011-01-15
RU2007127993A (ru) 2009-01-27
RU2454244C2 (ru) 2012-06-27
AU2005317683B2 (en) 2012-04-26
ES2356670T3 (es) 2011-04-12
US20080260773A1 (en) 2008-10-23
JP2008525423A (ja) 2008-07-17
US20150165019A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
GB0428394D0 (en) Saccharide conjugate vaccines
NO20064128L (no) Calicheamicinkonjugater
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
MY148763A (en) Anti-5t4 antibodies and uses thereof
NZ513840A (en) Vaccine
EA200702577A1 (ru) Способ изготовления вакцин
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
PE20110065A1 (es) Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
WO2007116409A3 (en) Improved vaccines comprising multimeric hsp60 peptide carriers
PE20071058A1 (es) Vacuna de streptococcus pneumoniae
EP2570137A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
TW200636064A (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
MX350230B (es) Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.
AR060187A1 (es) Composicion inmunogenica
AR080122A1 (es) Composicion de vacuna conjugada de polisacarido-proteina neumococica 15-valente
MX2009012381A (es) Composicion antigenica liofilizada.
WO2005028510A3 (en) Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
MX2015002483A (es) Composiciones inmunogenicas.
SG160336A1 (en) Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
AU2003302235A8 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
MX2023014282A (es) Conjugados de neodegradador-anticuerpo anti-cumulo de diferenciación 33 (cd33).
WO2022249107A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2024008039A (es) Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)